Drug pipeline
Explore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Hepatitis B virus surface antigen (HBsAg)
- Target
- HBsAg
- Molecular classification
- Glycoprotein, Integral membrane protein
01
Overview
Hepatitis B virus surface antigen is a critical structural glycoprotein essential for viral infectivity, pathogenesis, diagnosis, and prevention through vaccination. Its detection remains central to clinical management of hepatitis B infections worldwide.
- Other names
- Australia antigen
02
Mechanism of action
Neutralization of infectious virus particles by anti-HBs antibodies
03
Biological functions
Viral entry receptor bindingImmune evasion
04
Disease associations
InfectionLiver inflammationCirrhosisHepatocellular carcinoma
05
Biomarkers
HBsAg serum levels (diagnosis, monitoring)
Beyond the preview
Go deeper on Hepatitis B virus surface antigen (HBsAg).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Follow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Compare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Investigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Explore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Connect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Hepatitis B virus surface antigen (HBsAg).